SensiGen LLC is an Ann Arbor-based developer of gene-based molecular diagnostic tests.

In the news

San Diego-based Sequenom (NASDAQ: SQNM) disclosed in a regulatory filing it has issued 367,547 additional shares of its common stock, valued at $1.5 million, to settle claims stemming from its acquisition of Ann Arbor, MI-based SensiGen’s molecular diagnostic tests.

Assay's acquisition and San Diego-based Sequenom's $8.7 million acquisition of Ann Arbor-based SensiGen in January point to growing demand for companies capable of supplying critical testing kits to biotech researchers at universities and pharmaceutical companies.